IP Library › Granted Patent US 9,480,679
Granted Patent B2
US 9,480,679 · App. 13/395,255 · Granted Nov 1, 2016

Methods for treating malaria, tuberculosis and MAC diseases

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,480,679
App. No.
13/395,255
Granted
Nov 1, 2016
Kind
B2
Abstract

Described herein are formulations and methods for treating diseases caused by infectious pathogens, including mycobacterium avium complex, mycobacterium tuberculosis , Nocardia, Plasmodium falcium , and Plasmodium berghei.

Claims (18)

1. A method for treating a patient having a Mycobacterium avium complex, Mycobacterium tuberculosis , Nocardia, Plasmodium falciparum , or Plasmodium berghei infection, the method comprising the step of administering to the patient a therapeutically effective amount of a composition comprising CEM-101 or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 wherein the infection is a Mycobacterium tuberculosis, Plasmodium falciparum , or Plasmodium berghei infection.

3. The method of claim 1 wherein the patient is a human.

4. The method of claim 1 wherein the patient is a human, that is immunocompromised.

5. A method for treating malaria, the method comprising the step of administering to the patient a therapeutically effective amount of a composition comprising CEM-101

or a pharmaceutically acceptable salt thereof.

6. The method of claim 5 wherein the malaria is resistant.

7. The method of claim 5 wherein the composition comprises CEM-101.

8. The method of claim 1 wherein the composition comprises CEM-101.

9. The method of claim 8 wherein the infection is a Mycobacterium avium complex infection.

10. The method of claim 8 wherein the infection is a Mycobacterium tuberculosis infection.

11. The method of claim 8 wherein the infection is a Nocardia infection.

12. The method of claim 8 wherein the infection is a Plasmodium falciparum or Plasmodium berghei infection.

13. A method for treating a disease selected from the group consisting of tuberculosis, leprosy, and nocardiosis, the method comprising the step of administering to the patient a therapeutically effective amount of a composition comprising CEM-101 or a pharmaceutically acceptable salt thereof.

14. The method of claim 13 wherein the composition comprises CEM-101.

15. The method of claim 14 wherein the disease is tuberculosis.

16. The method of claim 14 wherein the disease is leprosy.

17. The method of claim 14 wherein the disease is nocardiosis.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 14, 2019
From: CEMPRA PHARMACEUTICALS, INC.
To: TETARD, INC.
Reel/Frame 050056/0731 →
RELEASE OF SECURITY INTEREST Recorded Jun 4, 2019
From: CORTLAND CAPITAL MARKET SERVICES LLC
To: CEMPRA PHARMACEUTICALS, INC.
Reel/Frame 049363/0706 →
SECURITY INTEREST Recorded Jan 8, 2018
From: MELINTA THERAPEUTICS, INC.; REMPEX PHARMACEUTICALS, INC.; CEMPRA PHARMACEUTICALS, INC.; CEM-102 PHARMACEUTICALS, INC.
To: CORTLAND CAPITAL MARKET SERVICES LLC, AS AGENT
Reel/Frame 045019/0552 →